GSK Pharmaceuticals completes transaction with Novartis

GlaxoSmithKline Pharmaceuticals acquires the Vaccines business of Novartis and divests its Oncology business to Novartis


The transaction will enhance GSK's vaccines portfolio

GlaxoSmithKline Pharmaceuticals (‘GSK India') announces completion of its transaction with Novartis Healthcare (‘Novartis India'), where GSK India acquires Novartis' vaccines business and divests its marketed oncology portfolio to Novartis India.

This follows a global transaction between GlaxoSmithKline plc, UK (GSK) and Novartis AG, Switzerland (Novartis) which was completed in March 2015 on the same basis.

The acquisition of the vaccines business of Novartis provides GSK with an exciting opportunity to build an even stronger, sustainable global vaccines business. The transaction will enhance GSK's vaccines portfolio and bring together its expertise in virology, bacterial infection and technological platforms to deliver a reliable supply of high quality vaccines.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email